Traduction de «detailed information about the product » (Néerlandais → Français) :

The Ministry of Public Health has, however, requested that a post-consumption follow-up be carried out and that the general public be given detailed information about the product’s adverse effects.
Le Ministère de la Santé a cependant demandé que soit mis en œuvre un suivi post-consommation et une information précise à l’attention du grand public sur les effets indésirables de ce produit.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.
In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.

The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.
The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.

Information about medicines and health products e-mail info.FAGG_AFMPS@fagg-afmps.be
Information about medicines and health products e-mail info.FAGG_AFMPS@fagg-afmps.be

Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.
Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.